Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (Nasdaq: BCAB) is a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, and its news flow reflects the progress of this platform. Company announcements regularly describe updates on CAB-based antibody-drug conjugates and bispecific T-cell engagers, regulatory interactions, financing arrangements, and strategic collaborations.
Recent BioAtla news has highlighted the clinical and regulatory path for ozuriftamab vedotin (Oz-V), a CAB-Platform ROR2-targeting ADC. Releases describe compelling Phase 2 data in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), FDA Fast Track Designation for certain squamous cell carcinoma of the head and neck patients, and FDA alignment on a randomized Phase 3 trial design with dual primary endpoints. Additional coverage explains a special purpose vehicle (SPV) transaction with Inversagen AI, LLC and GATC Health Corp. intended to fund a registrational Oz-V trial in OPSCC while BioAtla retains a majority ownership interest in the Oz-V asset.
News items also focus on mecbotamab vedotin (Mec-V), a CAB AXL-targeting ADC in Phase 2 development, including clinical data in treatment-refractory soft tissue sarcomas and mKRAS non-small cell lung cancer. For BA3182, a CAB EpCAM x CAB CD3 bispecific T-cell engager, BioAtla has reported preliminary Phase 1 results in metastatic adenocarcinoma patients, describing a manageable safety profile and prolonged tumor control at higher dose levels.
Investors following BCAB news will also see regular updates on financial results, cash runway, and capital structure. The company has announced Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement that provide flexible equity-linked financing, as well as a special meeting of stockholders to consider approval of potential share issuances and a possible reverse stock split. Additional releases discuss Nasdaq listing compliance milestones, patent coverage, and licensing agreements such as the worldwide license to Context Therapeutics for a CAB Nectin-4 x CD3 T-cell engager.
For those tracking oncology pipelines, regulatory milestones, and financing developments in clinical-stage biotech, the BioAtla news page offers ongoing detail on how the CAB platform and its lead programs are progressing. Investors and observers can use this stream of press releases to monitor trial design decisions, data presentations at major medical congresses, partnership activity and key corporate events related to BCAB stock.
BioAtla, Inc. (Nasdaq: BCAB) reported progress in its clinical trials and financial results for Q4 and full-year 2022. The company has cleared dose-limiting toxicity (DLT) observation periods for its CAB-AXL therapy (BA3011) in multiple studies, with significant readouts expected in the second half of 2023. Cash reserves stood at $215.5 million, sufficient for operations into 2025. However, the net loss increased to $106.5 million for 2022. BioAtla anticipates several milestones, including FDA interactions and the initiation of several Phase 2 trials, demonstrating a strong commitment to advancing its product candidates aimed at high unmet medical needs.
BioAtla, a clinical-stage biotechnology company, will host a conference call on March 23, 2023, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ending December 31, 2022. The company specializes in Conditionally Active Biologic (CAB) therapeutics aimed at treating solid tumors. This presentation will provide key business highlights and insights into its clinical programs, including two CAB candidates in Phase 2 trials.
Investors can access the results prior to the call on the company's website.
BioAtla, Inc. (Nasdaq: BCAB) announced the departure of President Scott Smith, who will become the CEO of Viatris. Smith, who joined BioAtla in 2018, will remain connected to the company as a Board member. The company expressed gratitude for his contributions, emphasizing his role in expanding operations and advancing clinical programs. BioAtla continues to develop its Conditionally Active Biologic (CAB) technology, applicable for solid tumors, and has two CAB programs in Phase 2 clinical testing. The company holds extensive patent coverage for its CAB technology with 704 patents worldwide.
BioAtla, Inc. (Nasdaq: BCAB) announced FDA clearance for its IND application to initiate a Phase 1 clinical study of BA3182, a bispecific T-cell engager targeting advanced adenocarcinoma. This innovative therapy addresses common adenocarcinoma types, including lung, breast, and prostate cancers. BA3182 shows significant therapeutic potential due to its high specificity binding under acidic tumor conditions, aiming to improve patient outcomes while minimizing toxicity. The company projects sufficient cash reserves to support operations into 2025 as they pursue critical milestones in this promising clinical program.
BioAtla, Inc. (Nasdaq: BCAB) announced encouraging interim results of Mecbotamab vedotin (BA3011) in a Phase 2 trial for PD-1 refractory non-small cell lung cancer (NSCLC), with a total of 29 patients enrolled. The company is set to initiate the Phase 2 part 2 study for Undifferentiated Pleomorphic Sarcoma (UPS) and continues to progress in the Phase 1 study of BA3071. BioAtla expects multiple significant milestones throughout 2023 and has a cash runway extending into 2025 to support its clinical programs.
Viatris Inc. (NASDAQ: VTRS) has appointed Scott A. Smith and Elisha W. Finney to its board of directors, succeeding retiring members Neil Dimick and Ian Read. Scott Smith, formerly President at Celgene, brings extensive experience in the biotechnology sector, while Finney has a strong financial background from her tenure at Varian Medical Systems. Both new directors are expected to enhance Viatris' strategy for growth and innovation in the pharmaceutical sector. The changes come as the company prepares to advance to its second phase post-Combination in November 2020.
BioAtla, a clinical-stage biotechnology company, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. The company will host a fireside chat and conduct one-on-one investor meetings on January 10, 2023, at 3:00 p.m. PST. BioAtla focuses on developing Conditionally Active Biologic (CAB) therapeutics for solid tumors. The firm boasts extensive patent coverage and currently has two first-in-class CAB programs in Phase 2 clinical testing, targeting AXL and ROR2.
BioAtla, Inc. (Nasdaq: BCAB) announced participation in the upcoming Jefferies London Healthcare Conference, taking place November 15-17, 2022. Scott Smith, President, and Sheri Lydick, Senior VP of Commercial Strategy, will engage in a fireside chat and one-on-one investor meetings on November 17, 2022, at 9:45 a.m. GMT. This event highlights BioAtla's innovation in Conditionally Active Biologic (CAB) antibody therapeutics aimed at treating solid tumors. The company boasts over 600 patents and is currently advancing two CAB programs in Phase 2 clinical testing, targeting AXL and ROR2.
BioAtla, a clinical-stage biotechnology company, announced the sale of 9,745,128 shares at $6.67 each, aiming for approximately $65 million in gross proceeds. The underwritten offering is expected to close around November 8, 2022, pending customary conditions. Proceeds will support research, Phase 2 trials for two antibody-drug conjugates, and general corporate purposes. Notable investors include Acuta Capital Partners and Janus Henderson Investors. J.P. Morgan is the book-running manager for this offering, which is registered under an effective Form S-3 with the SEC.
BioAtla, Inc. (Nasdaq: BCAB) announced promising interim results from its Phase 2 studies for mecbotamab vedotin (BA3011) in non-small cell lung cancer (NSCLC), showing significant antitumor activity. The company reported a cash balance of $178.1 million as of September 30, 2022, sufficient to fund operations into 2H24. R&D expenses increased to $19.8 million, while net loss widened to $25.8 million. Ongoing clinical programs include CAB-CTLA-4 (BA3071), with the third dosing cohort underway. A conference call will be held today at 4:30 PM ET for further details.